Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0735-1097(01)01751-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis.
Arch Gynecol Obstet
January 2025
Gynecology Department, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, S/N, 28040, Madrid, Spain.
Purpose: Uterine fibroids are the most common pelvic tumors in women, representing the primary indication of hysterectomy. Gonadotropin-releasing hormone (GnRH) antagonists represent a new therapeutic option for premenopausal women. The aim of this review is to evaluate the efficacy and safety of GnRH antagonists in the treatment of uterine fibroids (size reduction and symptom control).
View Article and Find Full Text PDFUpdates in nonhormonal therapy for perimenopausal and menopausal symptoms.
Curr Opin Obstet Gynecol
January 2025
Division of Complex Family Planning, Department of Obstetrics and Gynecology, Stanford University Medical Center, Stanford, California, USA.
Purpose Of Review: Perimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies.
View Article and Find Full Text PDFEffect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.
Maturitas
November 2024
Hormone Hamburg, Hamburg, Germany. Electronic address:
Objective: To report patient-reported quality-of-life (QOL) outcomes in the DAYLIGHT study.
Study Design: DAYLIGHT was a phase 3b, randomized, double-blind, 24-week, placebo-controlled study. Participants were women aged ≥40 to ≤65 years with moderate to severe vasomotor symptoms (VMS) considered unsuitable for hormone therapy (HT) (contraindications, caution, stoppers, or averse) randomized 1:1 to placebo or fezolinetant 45 mg once daily.
A systematic review of enrolment criteria and treatment efficacy for microvascular angina.
EuroIntervention
January 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Background: Microvascular angina (MVA) is an important contributor to morbidity and mortality in patients with non-obstructive coronary artery disease. Despite improvements in its recognition and diagnosis, uncertainty remains around the most effective treatment strategy, and more data are needed.
Aims: We aimed to evaluate the quality of patient selection in treatment studies of MVA and provide a contemporary overview of the evidence base for the treatment of MVA.
Effects of Hydrogen Sulfide at Normal Body Temperature and in the Cold on Isolated Tail and Carotid Arteries from Rats and TRPA1 Knockout and Wild-Type Mice.
Biomedicines
December 2024
Department of Thermophysiology, Institute for Translational Medicine, Medical School, University of Pecs, 7624 Pecs, Hungary.
Hydrogen sulfide (HS) is a gasotransmitter that modulates vascular tone, causing either vasodilation or vasoconstriction depending on the vascular bed, species, and experimental conditions. The cold-sensitive transient receptor potential ankyrin-1 (TRPA1) channel mediates HS-induced effects; however, its contribution to the vasomotor responses of different arteries at different temperatures has remained unclear. Here, we aimed to fill this gap by comparing the effects of sodium sulfide (NaS), which is a fast-releasing HS donor, on the isolated carotid and tail skin arteries of rats and mice at cold and normal body temperature with wire myography.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!